Background There is no standard systemic therapy for metastatic esophageal cancer
progressing after 1st/2nd line chemotherapy (Thallinger et al, 2011, JCO, 4709-14). High …

Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

4022 Background: Patients with advanced esophageal cancer have a poor prognosis.
Although chemotherapy is often employed as first-line treatment there is no standard therapy …

Background Conventional chemotherapeutic agents are of limited benefit in patients with
recurrent or metastatic cancer of the esophagus or gastroesophageal junction (GEJ). We …

Purpose The efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) gefitinib was assessed in a phase II study in patients with advanced …

Objective: The objective of this study is to evaluate the clinical efficacy and toxicity of gefitinib
single drug in treatment of advanced esophageal cancer. Materials and Methods: Forty-one …

4054 Background: Conventional chemotherapeutic agents are of limited benefit in patients
(pts) with recurrent or metastatic cancer of the esophagus or GEJ. We report preliminary …

Purpose: At presentation, most cases of adenocarcinoma of the esophagus (ACE) are
inoperable. Although chemotherapy can prolong survival, patients eventually die as a result …

4605 Background: Efficacy of chemotherapy and RT in patients with esophageal carcinoma
has been established in addition to surgical treatment. EGFR protein expression is prevalent …

4050 Background: There is increased recognition that cancers of the upper GI tract are
comprised of distinct epidemiological and molecular entities. Erlotinib (E) has shown activity …